AMRXQT71Amneal Pharmaceuticals, Inc.·NASDAQ
21.51+0.75%
TA
Loading chart...
Screen all →
Snapshot
Index—P/E43.90EPS (ttm)0.49Insider Own—Shs Outstand319.35MPerf Week5.54%
Market Cap6.87BForward P/E17.83EPS next Y1.21Insider Trans-0.25%Shs Float143.63MPerf Month7.17%
Enterprise Value9.52BPEG2.08EPS next Q0.24Short Float9.79%Perf Quarter14.11%
Income157.00MP/S2.20EPS this Y28.76%Short Ratio5.76Perf Half Y67.65%
Sales3.12BP/B58.71EPS next Y17.13%ROA4.17%Short Interest14.07MPerf YTD70.71%
Book/sh0.37P/C53.67EPS next 5Y21.11%ROE-326.75%52W High21.68 -0.78%Perf Year106.23%
Cash/sh0.40P/FCF83.77EPS past 3/5Y— -18.45%ROIC13.38%52W Low9.99 115.32%Perf 3Y448.72%
Dividend Est.—EV/EBITDA14.57Sales past 3/5Y10.92% 8.66%Gross Margin39.32%Volatility2.56% 2.99%Perf 5Y279.37%
Dividend TTM—EV/Sales3.05EPS Y/Y TTM—Oper. Margin12.93%ATR (14)0.63Perf 10Y—
Dividend Ex-Date—Quick Ratio1.44Sales Y/Y TTM9.29%Profit Margin5.05%RSI (14)67.65Recom2.35
Dividend Gr. 3/5Y—Current Ratio2.20EPS Q/Q20.00%SMA206.61%Beta1.23Target Price23.80
Payout0.00%Debt/Eq23.73Sales Q/Q9.79%SMA5012.49%Rel Volume0.97Prev Close21.35
Employees8,700LT Debt/Eq22.82EarningsNov 03SMA20036.64%Avg Volume2.84MPrice21.51
IPO DateMay 07, 2018Option/ShortYes / YesEPS/Sales Surpr.34.81% 3.64%Net Debt/EBITDA4.06Volume2,765,214Change0.75%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-29-26ReiteratedGoldman SachsBuy$21 → $24
Sep-23-26InitiatedOppenheimerOutperform$27
Sep-17-26ReiteratedBarclaysOverweight$16 → $20
Sep-09-26InitiatedLeerinkOutperform$23
Aug-03-26ReiteratedUBSBuy$23 → $25
Jul-31-26ReiteratedGoldman SachsBuy$19 → $21
Jul-15-26ReiteratedUBSBuy$19 → $23
May-20-26ReiteratedBarclaysOverweight$15 → $16
Apr-17-26InitiatedUBSBuy$19
Mar-02-26ReiteratedTruist SecuritiesBuy$15 → $17
Latest News· Times ET
Oct-27-26
Oct-26-26
Oct-24-26
Oct-13-26
Oct-10-26
Oct-09-26
Oct-08-26
Oct-03-26
Sep-28-26
Sep-23-26
Sep-22-26
Company

Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue3,1183,0192,7942,394—————
Cost of Goods Sold Incl. D&A1,8921,8831,7741,530—————
Gross Profit1,2261,1361,020864—————
Selling, General and Administrative Excl. Other572527476430—————
Research and Development177186191195—————
Other Operating Expense74010434—————
Operating Income404423249204—————
Interest Expense227241259211—————
Unusual Expense
—————————
Non-Operating Income (Expense)26-43-46-34—————
Net Income Before Taxes201139-55-40—————
Income Taxes-1411198—————
Consolidated Net Income15772-117-84—————
Net Income From Continuing Operations216128-74-49—————
Net Income15772-117-84—————
EPS (Recurring)0.500.23-0.38-0.48—————
EPS (Basic, Before Extraordinaries)0.500.23-0.38-0.48—————
EPS (Diluted)0.490.22-0.38-0.48—————
EBITDA653604440501—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio43.9057.27———————
Price To Sales Ratio2.201.310.880.44—————
Gross Margin39.3237.6336.5136.09—————
Operating Margin12.9614.018.918.52—————
Net Margin5.042.38-4.19-3.51—————
Shares Outstanding319313309175—————
Market Capitalization6,8623,9442,4471,062—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$23.34$19.37$15.40$11.42$7.45● Close Price0.00M1.80M3.61M5.41M7.22MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
BUCHI J KEVINDirectorSep 11 '26Option Exercise14.4520,445295,43095,522Sep 14
Kiely JohnDirectorAug 13 '26Sale17.6450,000882,000210,252Aug 14
Shah NikitaExecutive Vice PresidentAug 12 '26Sale17.51146,4032,563,517253,390Aug 13
Daly Jason B.EVP, Chief Legal OfficerAug 12 '26Sale17.40210,0003,654,00035,171Aug 13
BUCHI J KEVINDirectorAug 11 '26Option Exercise17.18168,5732,896,08493,499Aug 13
Daly Jason B.EVP, Chief Legal OfficerAug 11 '26Sale17.706,613117,050245,171Aug 13
Autor Deborah M.DirectorMay 11 '26Sale12.9434,819450,55893,660May 12
Yanai ShlomoDirectorMay 07 '26Option Exercise0.0034,8190320,804May 08
George Jeffrey P.DirectorMay 07 '26Option Exercise0.0034,8190344,614May 08
Patel GautamDirectorMay 07 '26Option Exercise0.0034,81901,643,963May 08
Kiely JohnDirectorMay 07 '26Option Exercise0.0034,8190260,252May 08
Nark Ted CDirectorMay 07 '26Option Exercise0.0034,8190325,848May 08
MEISTER PAUL MDirectorMay 07 '26Option Exercise0.0048,7470832,800May 08
BUCHI J KEVINDirectorMay 07 '26Option Exercise0.0034,819075,077May 08
Autor Deborah M.DirectorMay 07 '26Option Exercise0.0034,8190128,479May 08
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.